tetano
Editor, Senior Moderator
Pediatr Infect Dis J
. 2023 Dec 1;42(12):1136-1142.
doi: 10.1097/INF.0000000000004085. Epub 2023 Sep 4. Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine KCONVAC in Chinese Children: Randomized, Double-blind, Placebo-controlled Phase 1 and 2 Trials
Jiankai Liu[SUP] 1 [/SUP], Baoying Huang[SUP] 2 [/SUP], Guifan Li[SUP] 3 [/SUP], Tao Huang[SUP] 4 [/SUP], Danni Wang[SUP] 5 [/SUP], Li Zhang[SUP] 6 [/SUP], Yao Deng[SUP] 2 [/SUP], Xianyun Chang[SUP] 3 [/SUP], Yafei Liu[SUP] 3 [/SUP], Weiqi Li[SUP] 3 [/SUP], Siyuan Zhang[SUP] 4 [/SUP], Weijin Huang[SUP] 6 [/SUP], WenJie Tan[SUP] 2 [/SUP], Lidong Gao[SUP] 4 [/SUP]
Affiliations
Background: It is important to extend the indication of severe acute respiratory syndrome coronavirus 2 vaccine to children to improve the vaccine intake rate and reduce infection in this population.
Methods: In 2 phase 1 and phase 2 randomized, double-blind and placebo-controlled trials, 84 and 480 Chinese healthy children 3 to 17 years old were enrolled, respectively, and randomized in 3:1 ratio to receive 2 doses of a severe acute respiratory syndrome coronavirus 2 inactivated vaccine, KCONVAC or placebo. The 2 doses were given 28 days apart. Adverse events (AEs) were recorded through Day 28 after each dosing. Live virus neutralizing antibody and receptor binding domain antibody (RBD-IgG) were tested before vaccination and after the second dose.
Results: Two doses of the vaccine, KCONVAC, elicited geometric mean titers of 142-150 for neutralizing antibody and 4154-4253 for RBD-IgG 28 days after the second dose. Seroconversion rates were 100% after 2 doses for both antibodies in both trials. The predominant AEs were injection-site pain, cough and fever. Most AEs were grade 1 or 2 in intensity. Five participants reported 6 vaccination-unrelated serious AEs in the phase 2 trial.
Conclusions: Two doses of this study vaccine, KCONVAC, were well tolerated and immunogenic in children 3 to 17 years of age.
Trial registration: ClinicalTrials.gov NCT05003479.
. 2023 Dec 1;42(12):1136-1142.
doi: 10.1097/INF.0000000000004085. Epub 2023 Sep 4. Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine KCONVAC in Chinese Children: Randomized, Double-blind, Placebo-controlled Phase 1 and 2 Trials
Jiankai Liu[SUP] 1 [/SUP], Baoying Huang[SUP] 2 [/SUP], Guifan Li[SUP] 3 [/SUP], Tao Huang[SUP] 4 [/SUP], Danni Wang[SUP] 5 [/SUP], Li Zhang[SUP] 6 [/SUP], Yao Deng[SUP] 2 [/SUP], Xianyun Chang[SUP] 3 [/SUP], Yafei Liu[SUP] 3 [/SUP], Weiqi Li[SUP] 3 [/SUP], Siyuan Zhang[SUP] 4 [/SUP], Weijin Huang[SUP] 6 [/SUP], WenJie Tan[SUP] 2 [/SUP], Lidong Gao[SUP] 4 [/SUP]
Affiliations
- PMID: 37967148
- DOI: 10.1097/INF.0000000000004085
Background: It is important to extend the indication of severe acute respiratory syndrome coronavirus 2 vaccine to children to improve the vaccine intake rate and reduce infection in this population.
Methods: In 2 phase 1 and phase 2 randomized, double-blind and placebo-controlled trials, 84 and 480 Chinese healthy children 3 to 17 years old were enrolled, respectively, and randomized in 3:1 ratio to receive 2 doses of a severe acute respiratory syndrome coronavirus 2 inactivated vaccine, KCONVAC or placebo. The 2 doses were given 28 days apart. Adverse events (AEs) were recorded through Day 28 after each dosing. Live virus neutralizing antibody and receptor binding domain antibody (RBD-IgG) were tested before vaccination and after the second dose.
Results: Two doses of the vaccine, KCONVAC, elicited geometric mean titers of 142-150 for neutralizing antibody and 4154-4253 for RBD-IgG 28 days after the second dose. Seroconversion rates were 100% after 2 doses for both antibodies in both trials. The predominant AEs were injection-site pain, cough and fever. Most AEs were grade 1 or 2 in intensity. Five participants reported 6 vaccination-unrelated serious AEs in the phase 2 trial.
Conclusions: Two doses of this study vaccine, KCONVAC, were well tolerated and immunogenic in children 3 to 17 years of age.
Trial registration: ClinicalTrials.gov NCT05003479.